Cytokeratin immunoreactivity in gliomas

Area of Science:

• Neuroscience
• Oncology
• Immunohistochemistry

Background:

• Cytokeratins are intermediate filament proteins crucial for epithelial cell structure.
• Gliomas, including astrocytomas, oligodendrogliomas, and ependymomas, are primary brain tumors of glial origin.
• Immunohistochemistry is a vital tool in neuropathology for tumor classification and diagnosis.

Purpose of the Study:

• To investigate the expression of cytokeratin proteins in various glial tumors using specific monoclonal antibodies and polyclonal antisera.
• To evaluate the utility of the AE1/3 antibody in the differential diagnosis of brain tumors.

Main Methods:

• Immunohistochemical staining was performed on a series of astrocytic tumors (glioblastoma multiforme, anaplastic astrocytoma, well-differentiated astrocytoma), oligodendrogliomas, and ependymomas.
• Monoclonal antibodies (AE1/3, CAM 5.2, PKK-1) and polyclonal antisera targeting cytokeratins were utilized.

Main Results:

• The AE1/3 antibody showed immunoreactivity in 58% of glioblastoma multiforme, 63% of anaplastic astrocytomas, and 40% of well-differentiated astrocytomas.
• AE1/3 also stained astrocyte-like cells and neoplastic oligodendrocytes in 50% of oligodendrogliomas.
• Ependymomas were negative for all tested cytokeratin markers.
• Other anti-cytokeratin antibodies (CAM 5.2, PKK-1) did not yield positive results in these glioma subtypes.

Conclusions:

• The AE1/3 antibody detects cytokeratins in a subset of astrocytomas and oligodendrogliomas, suggesting potential co-expression with glial fibrillary acidic protein.
• These findings highlight the need for caution when employing AE1/3 in the differential diagnosis between gliomas and carcinomas.
• The distinct lack of cytokeratin expression in ependymomas supports their differentiation from other glial tumor types using these markers.